All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?
Bookmark this article
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the Lymphoma Hub was pleased to speak with Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain. We asked, What role is there for allogeneic stem cell transplant in the treatment of Hodgkin lymphoma?
What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?
Sureda begins by outlining some important considerations for allogeneic hematopoietic stem cell transplant such as the use of haploidentical donors. She highlights that the introduction of new drugs like brentuximab have had an impact on reducing the number of allogenic transplants occurring. Finally, she discusses how a better knowledge of how to combine checkpoint inhibitors with allogenic stem cell transplants has led to improvements in the long term outcome of patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox